New Publication: Clinical Overview of MDM2/X-Targeted Therapies

Great news, we have a new Mini-Review published in Frontiers Oncology entitled¬†“Clinical Overview of MDM2/X-Targeted Therapies“, which is apart of the Research Topic¬†Human tumor-derived p53 mutants: a growing family of oncoproteins Here is a little snippet from the Abstract to wet your appetite! MDM2 and MDMX are the primary negative regulators of p53, which under […]

Read More New Publication: Clinical Overview of MDM2/X-Targeted Therapies